1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 30,200 | 31,000 | 12.01. | |
| 29,400 | 31,200 | 12.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.12.25 | Anbio Biotechnology - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.08.25 | Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System | 151 | GlobeNewswire (Europe) | FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering... ► Artikel lesen | |
| 14.03.25 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 14.03.2025 | 952 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.03.2025
Aktien
1 KYG0367B1059 Anbio Biotechnology
2... ► Artikel lesen | |
| 20.02.25 | Anbio Biotechnology Announces Closing of Initial Public Offering | 366 | GlobeNewswire (Europe) | Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the "Company" or "Anbio"), a global diagnostic company dedicated to the advancement of medical technology and the... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 19.02.25 | Anbio Biotechnology Prices IPO Of 1.60 Mln Class A Ordinary Shares At $5.00/shr | 761 | AFX News | WASHINGTON (dpa-AFX) - Anbio Biotechnology said that it has priced its initial public offering of 1.60 million Class A ordinary shares at a public offering price of US$5.00 per Class A Ordinary... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANIGRAM GLOBAL | 1,450 | -2,03 % | Organigram Global Inc: Organigram increases Phylos loan by $3-million (U.S.) | ||
| ASSEMBLY BIOSCIENCES | 26,200 | -4,03 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 152,45 | +4,67 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue | Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY- preliminary 4Q and... ► Artikel lesen | |
| COMPASS PATHWAYS | 6,100 | -2,40 % | Compass Pathfinder Limited: Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD | FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues... ► Artikel lesen | |
| ALTIMMUNE | 3,440 | -0,32 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,775 | -0,21 % | Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer | SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,580 | +19,73 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| XORTX THERAPEUTICS | 0,518 | +3,81 % | XORTX Therapeutics Inc.: XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update | CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| KALA BIO | 0,521 | -2,62 % | KALA BIO, Inc. - 8-K, Current Report | ||
| GALECTIN THERAPEUTICS | 2,720 | +3,03 % | Galectin Therapeutics Inc.: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March ... | NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen | |
| SCYNEXIS | 0,583 | +0,52 % | SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement | JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 11,800 | -0,84 % | Wave Life Sciences Ltd. - 8-K, Current Report | ||
| IRONWOOD PHARMACEUTICALS | 3,880 | +11,49 % | Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating | ||
| XERIS BIOPHARMA | 6,800 | -0,29 % | Xeris Biopharma expects full-year 2025 revenue above estimates | ||
| THERAPEUTICSMD | 1,720 | -1,15 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.12.2025 | The following instruments on XETRA do have their first trading 10.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.12.2025
Aktien
1 JP3108030002 Axyz Co. Ltd.
2 JP3431200009... ► Artikel lesen |
Das Unternehmen ANBIO BIOTECHNOLOGY kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,400 (+1,33 %) liegt der Kurs bei 30,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANBIO BIOTECHNOLOGY finden Sie auf Wallstreet Online.